Efficacy of Tamsulosin and Tadalafil Combination Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia (BPH) without Erectile Dysfunction (ED)
Abstract
Introduction and Objective: Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) is quite complex to manage . Many drugs with various mechanisms of action are available Since erectile dysfunction commonly accompanies LUTS, drugs covering both these disorders shall be advantageous. We evaluated the efficacy of combination of tamsulosin and tadalafil in patients with LUTS without ED
Methodology: prospective randomized study in which patients with LUTS without any erectile dysfunction within the age group of 45 – 65 yrs and prostate gland size up to 50 cc were enrolled for three months and patients were assessed for International Prostatic Symptom Score (IPSS), quality of life (IPSS QoL), maximum urinary flow rate (Qmax) and post-void residual urine (PVR) volume before and at 3 months of treatment and this data was analysed
Results: Mean IPSS score in groups 1, 2, 3 & 4 were 22.81, 23.06, 23.30, 24.32 respectively which after three month drug treatment were noted to be 16.91, 11.31, 12.07 & 8.11. The difference in the maximum flow rate were statistically significant. Mean QoL scores before and after the study were 5.25, 4.81, 5.17 & 4.76 and 2.88, 2.15, 2.20 & 1.55 respectively , the change being statiscally significant (p < 0.001).The improvement in mean peak flow rate were also very remarkable. The mean Qmax rates initially in groups 1, 2, 3 & 4 were 10.81, 10.80, 10.77 & 10.82 ml/sec respectively which after three months became 11.62, 17.43, 12.75 & 18.86 ml/sec respectively. PVR reduced significantly in group 2 and 4.
Conclusion: From the results and analysis of our study we can conclude that combination Tadalafil and α-Blocker therapy is superior to tamsulosin or tadalafil alone for Benign Prostatic Hyperplasia in patients with LUTS even in patients not having erectile dysfunction for improving IPSS, QoL and Qmax significantly but not significant change in post-voidal residue.
When publishing with Kerala Medicial Journal (KMJ), authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Work includes the material submitted for publication and any other related material submitted to KMJ. In the event that KMJ does not publish said work, the author(s) will be so notified and all rights assigned hereunder will revert to the author(s).
The assignment of rights to KMJ includes but is not expressly limited to rights to edit, publish, reproduce, distribute copies, include in indexes or search databases in print, electronic, or other media, whether or not in use at the time of execution of this agreement.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
The author(s) hereby represents and warrants that they are sole author(s) of the work, that all authors have participated in and agree with the content and conclusions of the work, that the work is original, and does not infringe upon any copyright, propriety, or personal right of any third party, and that no part of it nor any work based on substantially similar data has been submitted to another publication.
